Brief: Median Technologies SA - Aims To Obtain Full Device Approval & Market Authorization By 2023 End For Ibiopsy® Lung Cancer Screening Cade/Cadx Software
03/03/2022 16:47
* MEDIAN TECHNOLOGIES SA - AIMS TO OBTAIN FULL DEVICE
APPROVAL &
MARKET AUTHORIZATION BY 2023 END FOR IBIOPSY® LUNG CANCER
SCREENING CADE/CADX SOFTWARE
* MEDIAN TECHNOLOGIES SA - FDA IS EXPECTED TO REVIEW 513(G)
SUBMISSION AND PROVIDE FEEDBACK WITHIN 60 CALENDAR DAYS
Source text for Eikon: ID:nBw19fPpQa
Further company coverage: [ ]
Recent news on Median Technologies SA
See all newsBrief: Median Technologies Forms Strategic Review Committee To Consider iCRO Separation, US Listing
France's Median Technologies H1 order backlog rises on demand from biopharmaceutical clients
Brief: Median Technologies H1 Revenue EUR 11.8 Million
Brief: Median Launches Eur 40 Mln Capital Raise To Fund Eyonis Rollout, Extend Runway To H1 2028
Brief: Median Technologies Reports FY Revenue EUR 23.5 Million